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Abstract
The occurrence of metastases to pelvic lymph nodes profoundly affects the prognosis of pelvic malignancies, making
accurate staging crucial for selecting appropriate treatment. Modalities for the detection of metastatic lymph nodes
are lymph node dissection, lymphangiography, and non-invasive techniques such as computed tomography (CT) and
magnetic resonance imaging (MRI); the role of these techniques will be reviewed. Although this review will focus on
prostate cancer, the statements may be generalised for other malignancies, as the metastases in pelvic lymph nodes
have a similar pattern for other tumors.
Introduction
The occurrence of metastases to pelvic lymph nodes
profoundly affects the prognosis of pelvic malignancies,
making accurate staging crucial for selecting appropriate
treatment. Modalities for the detection of metastatic
lymph nodes are lymph node dissection, lymphangio-
graphy, and non-invasive techniques such as computed
tomography (CT) and magnetic resonance imaging
(MRI); the role of these techniques will be reviewed.
Although this review will focus on prostate cancer, the
statements may be generalised for other malignancies,
as the metastases in pelvic lymph nodes have a similar
pattern for other tumors.
Pelvic lymph node dissection (PLND)
PLND has traditionally been an integral component of
prostate (pelvic) cancer staging. Pathological examina-
tion of lymph node tissue remains the gold standard for
determining whether or not lymph node metastases are
present. However, there has been recent interest in iden-
tifying patients for whom lymph node dissection may not
be justified on the basis of cost and potential morbidity [1].
PLND is an expensive, invasive procedure, with atten-
dant complications, and appears to have no therapeutic
value [2]. Reported complications of PLND are obturator
nerve injury, trauma to major vessels, thromboembolic
events, lymphocoele formation, chronic lower extremity
and genital edema and infection [3].
The advent of prostate specific antigen (PSA) screening
and increased clinical awareness have led to consid-
erable stage migration and a low incidence of lymph
node involvement in contemporary radical prostatectomy
series [4]. Multiple models and nomograms combining
PSA, clinical stage and Gleason score have been devel-
oped to predict the probability of metastatic disease [5–7].
Others have proposed PSA and Gleason score cut-off
points for selecting patients in whom the risk of nodal
disease is low, obviating the need for PLND. Essentially,
these cut-offs would define an acceptable percentage of
patients with potentially detectable metastatic disease
who would nevertheless undergo radical prostatectomy.
Currently, PLND is not carried out in patients deemed
to be at low risk for lymph node metastasis. Using a
false-positive rate of 3%, Bluestein et al. estimated that
25% of patients with clinically localised disease could
be spared PLND [6]. Rees et al. constructed a predictive
model to identify patients with less than 3% likelihood
of harboring lymph node disease [8]. Campbell et al.
observed similar results, in that 73% of their patients
were at low risk and the rate of positive lymph nodes
was only 2.2% [9]. How can an acceptable false-negative
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rate be defined if PLND is not carried out? When
using any of these models and nomograms, a small
percentage of patients harboring positive lymph nodes
are in the low-risk group and subsequently undergo
radical prostatectomy. It seems logical that the benefit of
omitting PLND in 50–70% of patients would outweigh
the 2–5% of patients with missed positive lymph nodes.
Rees et al. stated that physicians evaluating patients with
newly diagnosed prostate cancer should be willing to
accept a false-negative rate of 1.8% or less when deciding
whether to perform PLND for evaluation [8]. In general,
it is advisable to omit PLND in patients with PSA <10
ng/ml and Gleason score <7 [2,10–14], or PSA <20 ng/ml
and Gleason score <7 [10,15]. The threshold, however, has
only been evaluated objectively by Meng and co-authors
by using a formal decision analysis [16]. Even assuming
that PLND and frozen section analysis of lymph nodes is
100% sensitive, their model supports performing PLND
only in patients with a greater than 18% prevalence of
positive lymph nodes. The sensitivity of PLND is limited
by the fact that positive nodes will go unnoticed in 12%
of positive-node patients and 5% of patients subjected to
lymphadenectomy. This is caused by the fact that these
patients have isolated metastases to the common and
external iliac nodes, which are not included in the PLND
generally used in prostate cancer [17,18]. These findings
are supported by Barth et al. [19] and Weingartner [20].
They found that the detection of lymph node metastases,
and consequently the prognostic accuracy, is mainly
influenced by the total number of lymph nodes examined.
At least 13–20 nodes should be removed. Furthermore,
the efficacy of frozen section analysis of pelvic nodes has
also been questioned [21]. Reported false-negative results
are 100% [22], 40% [23], 33% [1,24–28], 30% [4,29], 23% [30],
19-7% [31].
Lymph node metastasis may be detected by methods
other than open PLND. Minimally invasive techniques,
such as laparoscopic and mini-laparotomy PLND, are
well described and provide comparable information and
improved patient recovery. Although the complication
rate of laparoscopic dissection is lower, it requires
general anaesthesia and hospitalisation. However, they
offer no advantage with respect to surgery time and
cost [9–12,32–36].
Staging lymph nodes: imaging
A non-invasive, reliable method for detecting and staging
nodal metastasis would reduce unnecessary surgery.
Currently, there are five imaging techniques described for
nodal staging: lymphangiography, CT, MRI, prostascint
radio-immunoscintigraphy, and 18FDG–PET. Bipedal
lymphangiography is no longer used as a screening
method, although it has the capacity to show micro
metastases in normal-sized nodes. Its inability to depict
internal iliac nodes and its potential invasiveness are
major drawbacks.
CT scanning and MRI
Cross-sectional imaging modalities like CT and MRI
have a low sensitivity (36%) [22,29,30,37–62] because both
modalities use the non-specific criterion of size to
distinguish between normal and malignant nodes, and
because both normal nodal and metastatic tissue have
the same signal intensity. The most generally accepted
criterion for a node to be metastatic on CT and MR
imaging is size. A minimal axial diameter of 10 mm or
less is considered to be normal.
Recently, three-dimensional high-resolution MRI tech-
niques have been used, which has allowed not only
determination of nodal size but also of nodal shape [3].
These authors considered round nodes with a minimal
axial diameter of more than 8 mm to be metastatic, in
addition to oval nodes with a size of more than 10 mm [49].
Using the additional feature of shape improved their
sensitivity to 75%. However in the same study, metastases
in normal-sized lymph nodes (25%) were still going
unnoticed.
Although fast dynamic MRI has been shown to
improve sensitivity by showing fast and high enhance-
ment in metastatic nodes, specificity has decreased. In
addition, fast dynamic is further limited by its low
resolution and pronounced vascular artifacts [63].
Thus staging PLND remains the most sensitive method
for assessing lymph node metastases and continues to be
the first step in the management protocol. Cost-effective
analysis performed by Wolf et al. [29] pointed out that
imaging should be restricted to patients with a high
probability of lymph node metastases. These authors
stated that when the probability of positive nodes based
on PSA level and clinical stage was 32%, the sensitivity
of the imaging method must be 36% to be beneficial.
When the sensitivity was 25%, as in their series, prior
probability should be 45%. Thus they concluded that
imaging was beneficial only when the pretest probability
of lymph node metastasis was high. The most important
parameter was the sensitivity of cross-sectional imaging
for lymph adenopathy. Pelvic imaging combined with
fine-needle aspiration has also been investigated. The data
of Wolf et al. suggest that only a subset of patients at
high risk for lymph node metastasis benefits from cross-
sectional imaging and preoperative lymph node sampling.
Prostascint radio-immunoscintigraphy and
18FDG–PET
Although very promising in metastatic lung cancer, the
role of 18FDG–PET scanning is limited in the urinary
tract region, as 18F-fluorodeoxyglucose accumulates as
part of the physiologic process in this area. This makes
an evaluation of metastases at this site difficult [64]. This
method is further limited by its low uptake in metastatic
nodes, especially in prostate cancer. In a study using PET
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in 64 patients with urinary bladder cancer, Bachor et al.
obtained a sensitivity of 67% and a negative predictive
value of 84%. In addition, their reported specificity of
86% is lower than those obtained with CT and MRI [65].
Heicappell et al. obtained a sensitivity of 65% with their
data [66].
With radio immunoscintigraphy (prostascint) in
patients with prostate cancer, Hinkle et al. and Manyak
et al. found a sensitivity of 75 and 62% respec-
tively [52,67].
Although the results of prostascint radio immunoscinti-
graphy and 18FDG–PET are slightly better than those of
CT and MR imaging, they are not high enough to replace
PLND. A negative prostascint scan may not eliminate the
need for PLND, due to low sensitivity for small volume
disease.
New developments: MRI after
intravenous injection of a lymph node
specific contrast agent
Previous reports have shown that the information about
lymph nodes on MR images can be improved by
pharmaceutical manipulation of tissue proton relaxation
times. Ultra small super paramagnetic iron oxide par-
ticles (USPIO) with a long plasma circulation time
have been shown to be suitable as an MR contrast
agent for intravenous MR lymphangiography [68,69]. After
intravenous injection, the USPIO particles are transported
to the interstitial space and from there through the
lymph vessels to the lymph nodes. Once within normally
functioning nodes, the iron particles are taken up by
macrophages; due to the T2∗—and susceptibility effect
of iron oxide, they reduce the signal intensity of
normal lymph node tissue in which they accumulate,
thus producing a negative enhancement. In areas of
lymph nodes that are involved with malignant cells,
macrophages are replaced by cancer cells, which lack
reticuloendothelial activity and are unable to take up the
USPIO particles. Other conditions in which the uptake
may be decreased include inflammatory nodes, as was
the case in two patients in our study. In addition, due to
increased vascular permeability and increased diffusion
in cancer tissue, there is leakage of USPIO particles
into the metastatic areas, which produces a low local
concentration and non-clustering of USPIO particles at
these metastatic sites [70]. Through their T1 relaxivity, this
can induce an increase in signal intensity on T1-weighted
images, producing positive enhancement [71–73]. Thus the
ability of post-contrast MRI to identify metastatic areas
in the lymph nodes depends primarily on the degree
of uptake of USPIO by the macrophages in normal
lymph node tissue and the leakage of USPIO particles
in the metastatic area itself. Twenty-four hours after
intravenous injection of USPIO, normal lymph node and
malignant tissue have different signal intensities on MR
images, thus this non-invasive technique may result in the
detection of metastatic deposits in normal-size nodes [71].
Thus far only two papers have appeared using this tech-
nique in the evaluation of pelvic malignancies, reporting
a sensitivity of 82 and 86% [71,74]. Other papers include
lymph node evaluation in other areas, predominantly
head and neck and chest. Reported sensitivities (mean
91%, range 84–100%) are higher compared to pre-
contrast MRI [75–79]. As these authors did not use high-
resolution techniques, they had limited visualisation of
small (<8 mm) lymph nodes.
A pilot study was performed at Mass General in
Boston, Charite in Berlin and UMC in Nijmegen, on
patients with histologically proven bladder and prostate
cancer. High-resolution techniques (at 1.5 T using a body
phased-array coil) on post-USPIO MRI significantly
improved the rate of detection of small nodal metastases
in normal-sized nodes (<8 mm). Normal nodal tissue
showed signal loss 24–36 h post injection. Metastases
showed equal or higher signal. The 3D T1-weighted
sequence vessels, especially veins, showed high signal
intensity, thus facilitating separation from nodes. On
the T2∗-GRE sequence in most patients the vessels
showed low signal intensity. Sensitivity and accuracy
and negative predictive value showed a significant
improvement, using post USPIO, to 85, 87 and 92%. This
was due to the detection of metastases in normal-size
nodes. During the slow (30 min) infusion of the USPIO
contrast, only two patients showed minor side effects (low
back pain), caused by too rapid an infusion. After slowing
down the infusion rate the symptoms decreased, and no
further treatment was needed.
Conclusions
PLND is unnecessary in the subset of patients in whom
the risk of lymph node involvement is less than 18%. CT
and MRI do not have the desired sensitivity in identifying
metastases to replace PLND. Only patients at very high
risk (36%) for lymph node metastasis benefit from
CT and MRI using preoperative fine-needle aspiration
biopsy of enlarged nodes. Although new techniques like
prostascint radio immunoscintigraphy and 18FDG–PET
have a higher sensitivity than CT and MRI, it is not
high enough to replace PLND. Initial results with MR
lymphography show a promising sensitivity (85%) and
negative predictive value (92%) in the detection of nodal
metastases of prostate and bladder cancer. If the results
of a pilot study can be confirmed in a multicenter study,
PLND may be avoided in most patients with prostate
cancer.
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